ViroPharma To Buy Lev For $443 Million | Chemical & Engineering News
Volume 86 Issue 29 | p. 24 | Concentrates
Issue Date: July 21, 2008

ViroPharma To Buy Lev For $443 Million

Department: Business
News Channels: Environmental SCENE

ViroPharma, in Exton, Pa., has reached an agreement to acquire Lev Pharmaceuticals, a New York City-based biopharmaceutical firm focused on developing treatments for inflammatory diseases, for an up-front payment of $442.9 million. Lev's Cinryze, a C1 inhibitor therapy for patients with hereditary angiodema, is currently under FDA review. Lev shareholders are also eligible for up to $175 million in regulatory and commercial milestone payments.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment